Paul Audhya Sells 5,354 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,354 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the sale, the insider owned 138,983 shares of the company’s stock, valued at approximately $2,163,965.31. This represents a 3.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of NASDAQ:KALV opened at $15.76 on Thursday. The company has a 50 day moving average price of $15.49 and a two-hundred day moving average price of $13.95. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22. The company has a market capitalization of $796.67 million, a PE ratio of -3.99 and a beta of -0.19. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.00.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds have recently bought and sold shares of KALV. BNP Paribas Financial Markets grew its position in shares of KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at $55,000. Wolverine Asset Management LLC acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $57,000. KLP Kapitalforvaltning AS acquired a new position in KalVista Pharmaceuticals in the 3rd quarter valued at $63,000. Finally, Truvestments Capital LLC increased its position in KalVista Pharmaceuticals by 253.8% during the 4th quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock worth $76,000 after buying an additional 3,360 shares during the period.

Key Stories Impacting KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Analyst optimism — Several firms have raised targets or reiterated buy ratings (Needham, HC Wainwright, TD Cowen) and MarketBeat shows a consensus price target (~$29.40) well above the current level, supporting upside expectations and investor interest. Read More.
• Positive Sentiment: Institutional accumulation — Recent 4Q filings show new or larger stakes by professional investors (examples cited by MarketBeat), which can provide a fundamental bid under the stock and validate management’s clinical programs. Read More.
• Neutral Sentiment: Speculative upside narrative — A Zacks piece highlights an implied ~117% upside based on consensus targets; useful for headline-driven flows but speculative and dependent on future clinical/earnings revisions rather than an immediate catalyst. Read More.
• Negative Sentiment: Concentrated insider selling — Multiple executives sold shares on Feb. 23 (CEO Benjamin Palleiko, CFO Brian Piekos, and others), a pattern that can raise short-term concern among investors even if sales are for diversification or tax reasons. These filings were recently posted to the SEC/InsiderTrades feed. Read More.

Analyst Ratings Changes

Several research firms have recently commented on KALV. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Citizens Jmp cut their price target on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research note on Tuesday, November 11th. Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Wall Street Zen raised shares of KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Finally, HC Wainwright raised their target price on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Friday, January 9th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.